Vaccine maker BioNTech says no need to waive patents
FILE - In this Saturday, Feb. 13, 2021 file photo the logo on the BioNTech biotechnology company displayed at the building where production of the COVID-19 vaccine has started, in Marburg, Germany. German pharmaceutical company BioNTech reported a net profit of 1.13 billion euros, about 1.37 billion US dollars, in the first quarter of this year on the back of strong revenues from its coronavirus vaccine. (AP Photo/Michael Probst, file)

FILE - In this Saturday, Feb. 13, 2021 file photo the logo on the BioNTech biotechnology company displayed at the building where production of the COVID-19 vaccine has started, in Marburg, Germany. German pharmaceutical company BioNTech reported a net profit of 1.13 billion euros, about 1.37 billion US dollars, in the first quarter of this year on the back of strong revenues from its coronavirus vaccine. (AP Photo/Michael Probst, file)

May. 10, 2021 09:21 AM EDT
A woman receives dose of the Pfizer vaccine against the coronavirus and the Covid-19 disease in a tent at the mobile vaccination centre in the Great Linden Hall of the town hall in Markkleeberg, Germany, Monday, May 10, 2021. (Jan Woitas/dpa via AP)

A woman receives dose of the Pfizer vaccine against the coronavirus and the Covid-19 disease in a tent at the mobile vaccination centre in the Great Linden Hall of the town hall in Markkleeberg, Germany, Monday, May 10, 2021. (Jan Woitas/dpa via AP)

May. 10, 2021 08:36 AM EDT